Open access peer-reviewed chapter

Preclinical and Clinical Developments in Molecular Targeting Therapeutic Strategies for Breast Cancer

By Teruhiko Fujii, Hiroki Takahashi, Yuka Inoue, Masayoshi Kage, Hideaki Yamana and Kazuo Shirouzu

Submitted: November 12th 2010Reviewed: July 16th 2011Published: December 14th 2011

DOI: 10.5772/21245

Downloaded: 1246

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Teruhiko Fujii, Hiroki Takahashi, Yuka Inoue, Masayoshi Kage, Hideaki Yamana and Kazuo Shirouzu (December 14th 2011). Preclinical and Clinical Developments in Molecular Targeting Therapeutic Strategies for Breast Cancer, Breast Cancer - Recent Advances in Biology, Imaging and Therapeutics, Susan J. Done, IntechOpen, DOI: 10.5772/21245. Available from:

chapter statistics

1246total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Translational Research on Breast Cancer: miRNA, siRNA and Immunoconjugates in Conjugation with Nanotechnology for Clinical Studies

By Arutselvan Natarajan and Senthil Kumar Venugopal

Related Book

First chapter

EGFR-Ligand Signaling in Breast Cancer Metastasis: Recurring Developmental Themes

By Nicole K. Nickerson, Jennifer L. Gilmore, Kah Tan Allen, David J. Riese II, Kenneth P. Nephew and John Foley

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us